Navigation Links
DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI--(MARKET WIRE) -- July 02, 2007 -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") announced today that the first results from testing of a multivalent form of its botulinum toxin vaccine, BT-VACC™, have been published in the journal Infection and Immunity (Ravichandran et al., 2007, Infection and Immunity, v. 75, p. 3043 ). These results are the first that describe the protective immunity elicited by a multivalent vaccine that is active by the mucosal route. The vaccine consists of a combination of three non-toxic subunits of botulinum toxin that induced protection against the corresponding versions of the natural toxins.

The results published in Infection and Immunity show that non-toxic subunits (protein components of the natural toxin) of three of the serotypes of botulinum toxin that cause almost all instances of human disease, namely serotypes A, B, and E, can be combined and delivered via nasal administration. The combination vaccine induced antibodies in the serum of mice and protected against subsequent exposure to high doses of a combination of the natural A, B, and E serotype neurotoxins. Further, the combination vaccine can induce protection when given mucosally as a booster to animals that have been given a primary vaccine injection.

BT-VACC™ is composed of a component of what is known as the heavy chain of each of the A, B, and E serotypes. These components lack the region of the toxin that are responsible for blocking neurotransmitter functions. The subunits can bind avidly to receptors on the surface of mucosal cells and traverse lung and gastrointestinal tissue to stimulate immunity. Because the binding subunits lack the toxic part of the molecule, the vaccine is safe and stimulates antibodies in not only the blood but those antibodies that coat mucosal surfaces. It is thought that antibodies that are present in lung and gastrointestinal secretions wil
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/30/2014)... Sept. 30, 2014 Arbor Pharmaceuticals, LLC. ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - ... of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Arbor ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects ... ... Population, SAN FRANCISCO, June 7 ... type 2 diabetes,that were enrolled in a Phase III study showed ...
... the ADA,s Annual Scientific Sessions, SAN FRANCISCO, ... of the dose-finding study for its new,injectable diabetes ... American Diabetes Association,s (ADA) 68th Annual Scientific Sessions,meeting ... that AVE0010 was well tolerated and significantly,improved glycemic ...
Cached Medicine Technology:Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 2Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 3Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
(Date:10/1/2014)... Wi (PRWEB) October 01, 2014 UP4 ... of UP4 WOMEN’S probiotic to The National Network to ... of October. This organization was chosen through nationwide polling ... website and social media outlets. , “We are ... receive a portion of every sale of UP4 Women’s ...
(Date:10/1/2014)... This weekend Pope Francis drew world-wide attention to the problem ... seniors in St. Peter's Square in the Vatican, he decried ... the elderly is as inhuman as that against children," Pope ... discarded, victims of an abandonment that is tantamount to hidden ... is hurting our world so much," he said. , His ...
(Date:10/1/2014)... Los Angeles, CA (PRWEB) October 01, 2014 ... buyer power score of 3.1 out of 5, ... freezer users include food and beverage manufacturers, food ... manufacturers. As a result of these users' diversity, ... growth. As such, rising industrial production, consumer spending ...
(Date:10/1/2014)... 01, 2014 Nearly a year-and-a-half after ... County District Court jury awarded him $4.75 million; Michael ... years old. Casper had been too sick to ... According to the Court Documents (District Court, Pueblo County ... a benign non-cancerous condition of his prostate, when he ...
(Date:9/30/2014)... (HealthDay News) -- There,s no genetic evidence that high ... a new study says. Some previous research had ... people against type 2 diabetes, raising the possibility of ... sugar disease. In this study, British researchers investigated ... focusing on genes that control blood levels of vitamin ...
Breaking Medicine News(10 mins):Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2Health News:Pope Francis Shines New Spotlight on Neglect of Elderly, Survey Finds Elder Self-Neglect is a Growing and Hidden Problem in U.S. says NAPGCM 2Health News:Pope Francis Shines New Spotlight on Neglect of Elderly, Survey Finds Elder Self-Neglect is a Growing and Hidden Problem in U.S. says NAPGCM 3Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 4Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 3Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2
... Mii amo, a destination spa,at Enchantment Resort, for ... the winter solstice on December 21. Activities include ... Native,American Program Director R.J. Joseph and special guest, ... Elder from the Blood Reserve,in Standoff, Alberta, Canada,s ...
... planned bequest comes at stem cell symposium, ANN ... retail pioneer A. Alfred Taubman announced a $22 million ... research institute aimed at,understanding, treating and preventing human disease., ... it again --,announcing that he will bequeath an additional ...
... a Man Wanted to Know But Was Afraid to ... 4.3 million babies born,in the U.S. each year but ... BEING DAD is a revealing, entertaining and inspirational DVD ... who,have recently gone through the pregnancy and delivery process. ...
... developed a magnetic resonance imaging (MRI)-based method for detecting and ... in patients who have undergone a procedure to treat atrial ... Oct. 7, 2008, issue of the Journal of the ... is an arrhythmia, or abnormal heart rhythm, that involves the ...
... (OTCBB:WYND), the ideas-to-revenues social media company, announced ... www.muveinc.com ), to create an interactive marketing ... corporate wellness program. Wyndstorm,s design project will ... use of wellness programs among employees via ...
... 7 The Catholic Health,Association of the United ... (CHI), Denver; Covenant Health Systems, Lexington, MA;,and Trinity ... effort to,raise awareness about global climate change., ... National Religious,Partnership for the Environment (NRPE) and the ...
Cached Medicine News:Health News:Mii amo Honors Winter Solstice With Traditional Native American Celebration December 18-21 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:BEING DAD DVD Offers a Sneak Peek at Pregnancy From a Guy's Point of View 2Health News:Novel imaging approach may assist in predicting success of treatment for atrial fibrillation 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3Health News:Catholic Health Organizations Launch Ministry-Wide Effort to Raise Awareness About Global Climate Change 2
DNA/RNA preparation in 8-multi channels...
... units with hydrophobic PTFE membranes,Millex filter ... ideal for the sterilizing filtration of ... and for sterilizing or clarifying organic ... filter units are available with different ...
... Bottled Water, The Simplicity personal water system ... currently use bottled water. In addition to ... store bottled water, your laboratory applications may ... be absorbed from containers and cause water ...
... of Type I ultrapure water, , Ultrapure ... System is designed to provide the "final ... by reverse osmosis, distillation or deionization. Super-Q ... which exceeds Type I ASTM/CAP/NCCLS specifications.,The Super-Q ...
Medicine Products: